Skip to content

Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition

Research output: Contribution to journalArticle

Original languageEnglish
Number of pages6
JournalMedicinal Chemistry
Early online date10 Jan 2020
DOIs
DateAccepted/In press - 8 Jan 2020
DateE-pub ahead of print (current) - 10 Jan 2020

Abstract

Klebsiella pneumoniae carbapenemase-2 (KPC-2) is a serine-β-lactamase (SBL) capable of hydrolysing almost all β-lactam antibiotics. We compare KPC-2 inhibition by vaborbactam, a clinically-approved monocyclic boronate, and VNRX-5133 (taniborbactam), a bicyclic boronate in late-stage clinical development. Vaborbactam inhibition is slowly reversible, whereas taniborbactam has an off-rate indicating essentially irreversible complex formation and a 15-fold higher on-rate, although both potentiate β-lactam activity against KPC-2-expressing K. pneumoniae. High resolution X-ray crystal structures reveal closely related binding modes for both inhibitors to KPC-2, with differences apparent only in positioning of the endocyclic boronate ester oxygen. The results indicate the bicyclic boronate scaffold as both an efficient, long-lasting, KPC-2 inhibitor and capable of supporting further iterations that may improve potency against specific enzyme targets and pre empt the emergence of inhibitor resistant KPC-2 variants.

Download statistics

No data available

Documents

Documents

  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Rpyal Society of Chemistry at https://pubs.rsc.org/en/Content/ArticleLanding/2020/MD/C9MD00557A#!divAbstract. Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 520 KB, PDF document

DOI

View research connections

Related faculties, schools or groups